Priyanka Pathania

B.Tech Biotech

1. History

2. Board of Directors

3. Products

4. SWOT Analysis

5. Data Analysis

6. Conclusion

Table of contents

Brief History

• The Himalaya Drug Company is a companyestablished by Mr. M. Manal in 1930 and basedin Bangalore, India. It produces health care productsunder the name Himalaya Herbal Healthcare, whichinclude Ayurvedic ingredients. It is spread acrosslocations in India, the United States, the Middle East,and Europe, while its products are sold in 60 countriesacross the world.

• The company has 70 researchers that study ayurvedicherbs and minerals. An Hepatic drug, named Liv.52, isits flagship product, first introduced in 1955.

Board of directors

• Mr. M. Manal ----- Founder

• Mr. Philipe Haydon ----- CEO

• Dr. S. Farooq ----- President

• Dr. Zafar Mehmood ------- Sr. Manager

Products

Pharmaceuticals :-

• Liv. 52

• Koflet

• HiOra-K Mouthwash

Animal Health :-

• furglow

• Himcal

• Himtox

Baby Care :-

• Baby Cream

• Baby Lotion

• Gentle Baby Shampoo

Nutrition Health :-

• HiOwna-Jr.

• HiOwna

STRENGTHS WEAKNESSES

Strong financial back up

Qualified staff.

Providing our costumers what they want.

Targeting both urban and rural markets.

Eco friendly herbal product.

Use of natural fluoride in place of fluoride

used up by other companies.

Due to high price of the product it may be

unaffordable for people of rural areas to pay

for the product.

Ayurvedic product.

Giant competitors in the market like

Colgate ,Pepsodent that are already establish

in the market.

SWOT analysis

OPPORTUNITIES THREATS

High investment and growth.

Growth will occur because of eco friendly

toothpaste.

As it is a daily usable commodity so

company is using intensive distribution

technology So that it will available at every

shop due to which sales of company's product

will be increased day by day.

As the world is becoming a global village so

company had also opportunities to grow

globally.

As the company is entering into new

market and launching a new product so there

is always chances of failure of the product.

Company have to face a lots and lots of

competition from the competitors already

present the market.

It is an Ayurvedic product and there are so

many international companies present in the

market so it is threat for the company.

Market shares

• In face washes, for instance, Himalaya has an all-India market share of 17.8 per cent, behind Lever and L’Oreal at 19.3 per cent each, according to Nielsen’s June audit report.

• In lip care, it is the second largest brand in India with a 14.6 per cent share, though in urban ,it registered as the largest brand with a 45 per cent share in the first quarter of 2010.

• In toothpaste, a crowded category with strong herbal competitors like Dabur, it was the fourth-largest brand in the modern trade format in Q1.

• Overseas, in the United Arab Emirates, Nielsen’s audit report shows that Himalaya Face Wash leads the category with a 20.8 per cent market share, ahead of multinationals Johnson & Johnson, Nivea and Olay.

• In face masks, Himalaya leads with 35.9 per cent share, significantly ahead of Montagne Jeunesse(18.3 per cent) and Fair & Lovely (8.5 per cent).

Shareholders

category of

Shareholder

No. of

Share-

holders

Total NO.

of Shares

Total No. of

Shares held in

Dematerialized

Form

Total

Shareholding

as a % of

total No. of

Shares

As a % of

(A+B)

As a % of

(A+B+C)

Shares

pledged or

otherwise

encumbered

Number of

shares

As a % of

Total

No. of

Shares

(A) Shareholding of Promoter and Promoter Group

(1) Indian

Bodies Corporate 3 4,211,449 4,209,149 8.05 8.05 - -

Any Others

(Specify)

14 13,425,619 13,415,919 25.67 25.67 - -

Directors/Promoters

& their Relatives &

Friends

14

13,425,619 13,415,919 25.67 25.67 - -

Sub Total 17 17,637,068 17,625,068 33.72 33.72 - -

(2) Foreign

Bodies Corporate 1 896,100 - 1.71 1.71 - -

Sub Total 1 896,100 - 1.71 1.71 - -

Total shareholding

of Promoter and

Promoter Group

(A)

18 18,533,168 17,625,068 35.44 35.44 - -

(B) Public Shareholding

(1) Institutions

Financial

Institutions / Banks

1 180 180 - - - -

Foreign

Institutional

Investors

1 2,400,000 - 4.59 4.59 - -

Sub Total 2 2,400,180 180 4.59 4.59 - -

(2) Non-Institutions

Bodies Corporate 287 5,291,071 5,268,871 10.12 10.12 - -

Individuals - - - - - -

Individual

shareholders

holding nominal

share capital up to

Rs. 1 lakh

15,340

9,089,693 8,000,910 17.38 17.38 - -

Individual

shareholders

holding nominal

share capital in

excess of Rs. 1 lakh

188

9,668,261 9,629,361 18.49 18.49 - -

Any Others

(Specify)

890 7,317,833 2,401,495 13.99 13.99 - -

Clearing Members 35 34,069 34,069 0.07 0.07 - -

Overseas Corporate

Bodies 3

4,402,613 - 8.42 8.42 - -

Hindu Undivided

Families 338

905,635 905,635 1.73 1.73 - -

ESOP/ESOS/ESPS 143 194,025 - 0.37 0.37 - -

Trusts 2 1,001,000 1,001,000 1.91 1.91 - -

Non Resident

Indians 369

780,491 460,791 1.49 1.49 - -

Sub Total 16,705 31,366,858 25,300,637 59.97 59.97 - -

Total Public

shareholding (B)

16,707 33,767,038 25,300,817 64.56 64.56 - -

Total (A)+(B) 16,725 52,300,206 42,925,885 100.00 100.00 - -

(C) Shares held by

Custodians and

against which

Depository Receipts

have been issued-m

- - - - - - -

(1) - - - - - -

(2) - - - - - -

Sub Total - - - - - -

Total (A)+(B)+(C) 16,725 52,300,206 42,925,885 - 100.00 - -

PERSONALITY TRAITS OF FOUNDER AND PROBLEMS FACED

Mr M. Manal was the founder of Himalaya company.

• He was a visionary and a real hero. He had a clear vision to bring Ayurveda to society in a contemporary form and to unravel the mystery behind the 5,000 year old system of medicine.

• This included referring to ancient ayurvedic texts, selecting indigenous herbs and subjecting the formulations to modern pharmacological, toxicological and safety tests to create new drugs and therapies.

• In 1930, on a visit to Burma, Mr. Manal saw restless elephants being fed with a root to pacify them. The plant from which this was taken is Rauwolfiaserpentina. Fascinated by the plant's effect on elephants, he had it scientifically evaluated.

• After extensive research, Serpina the world's first anti-hypertensive drug was launched in 1934.

Problem faced• It is an ayurvedic product and there are so many

international companies present in the market so it is threat for the company.

• Due to high price of the product it may be unaffordable for people of rural areas to pay for the product.

• Ayurvedic product.

• There are no shortcuts to success.

• Work hard, go out and experience the world. Let the working environment be your teacher.

• With no money and only a pocketful of dreams, he pawned his mother's jewellery to buy a hand-operated tableting machine